An update in neoadjuvant chemotherapy in cervical cancer

Panici, P. Benedetti; Bellati, Filippo; Pastore, M.; Manci, Natalina; Musella, Angela; Pauselli, Simona; Angelucci, Michela; Muzii, Ludovico; Angioli, Roberto

doi:10.1016/j.ygyno.2007.07.041

Cited by 38 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Toxicity was acceptable [7]. Other studies also found promising results, especially for platinum-based chemotherapy in combination with paclitaxel for the treatment of invasive squamous cervical cancer [8,9].…”

Section: Discussionmentioning

confidence: 99%

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Amant

Nooij

Annibali

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy for patients with vulvar cancer. Two patients with locally advanced disease had an impressive response allowing standard vulvar cancer surgery. One patient with metastatic disease had local stable disease though it was progressive in the lymph nodes. The available literature is sparse and retrospective. Based on promising results, however, a prospective multicenter study is mandatory in order to obtain full data in a larger series of patients in order to learn the benefits of neoadjuvant paclitaxel-carboplatin and compare the results with chemoradiation.

show abstract

Section: Discussionmentioning

confidence: 99%

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Amant

Nooij

Annibali

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Among chemotherapeutic agents, cisplatin still is the most frequently used drug and the one with the better results in terms of response rate [7,8]. A Cochrane meta-analysis published in 2004 [9] revealed that NACT followed by RS resulted in better disease-free and overall survival when compared to radiotherapy alone.…”

Section: Introductionmentioning

confidence: 99%

“…Taxol-cisplatin (TP) is the most commonly used drug combination and represents a valid alternative to the TIP regimen, showing an acceptable toxicity profile [8]; however, a lower response rate even though in the absence of significant differences in survival data was underlined in a phase II randomized trial [11]. Indeed, there is a need for an alternative NACT regimen, possibly characterized by an equal or superior efficacy with a lower toxicity profile with respect to standard TIP.…”

Section: Introductionmentioning

confidence: 99%

Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study

Panici

Palaia²,

Marchetti

et al. 2015

Oncology

Self Cite

View full text Add to dashboard Cite

Objective: To assess the efficacy and toxicity profile of dose-dense cisplatin-based neoadjuvant chemotherapy (NACT) followed by radical surgery in patients affected by locally advanced cervical cancer. Methods: Patients affected by carcinoma of the uterine cervix FIGO (International Federation of Obstetrics and Gynecology) stage IB2-IIIB were enrolled into the study. The treatment schedule consisted of 5 cycles of intravenous paclitaxel 60 mg/m² plus cisplatin 60 mg/m² every 10 days; patients were then submitted to radical hysterectomy and pelvic lymphadenectomy. Results: From January 2011 to March 2013, 22 patients were enrolled. Median age was 47 (26-83) years. FIGO stages included 1 IIA, 15 IIB, 1 IIIA, and 5 IIIB. Ninety-one percent of patients completed all the 5 planned cycles of NACT. Three patients experienced allergic reactions to paclitaxel. Grade 3-4 hematological toxicity was observed in 18% of cases. In 3 cases, grade 3-4 extra-hematological adverse and life-threatening events were reported (1 ototoxicity, 1 transient ischemic attack, and 1 myocardial infarction). No treatment-related death occurred. The operability rate was 86.4%. The overall response rate was 52.6%: 5 patients (26.3%) experienced clinical complete response, and 5 (26.3%) showed a clinical partial response. Stable disease was observed in 47.4% of patients, with no progressive disease recorded. Pathological response was observed in 57.9% of cases. Six out of 19 (31.6%) patients were submitted to adjuvant treatment. Conclusion: Dose-dense cisplatin-based NACT showed a response rate in approximately half of patients. However, in consideration of the reported extra-hematological toxicity, further studies on and new strategies with dose-dense platinum-based NACT are required to improve outcome in cervical cancer patients.

show abstract

“…30,31 Some centers use neoadjuvant chemotherapy in "bulky" cervical cancers with the aim of downstaging before radical hysterectomy. 76,77 Currently, four approaches have been published on neoadjuvant chemotherapy and fertility sparing surgery. All the published studies were different in terms of the surgical radicality used after neoadjuvant chemotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…76,77 Currently, three approaches have been published on neoadjuvant chemotherapy and fertility sparing surgery. First, Maneo and colleagues used neoadjuvant chemotherapy before fertility sparing surgery ( conisation ).…”

Section: 21neoadjuvant Chemotherapymentioning

confidence: 99%

Fertility preserving treatments in different prognostic groups of cervical cancer patients

Balázs¹

View full text Add to dashboard Cite

show abstract

An update in neoadjuvant chemotherapy in cervical cancer

Cited by 38 publications

References 24 publications

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study

Fertility preserving treatments in different prognostic groups of cervical cancer patients

Contact Info

Product

Resources

About